nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—ADRA2B—Platelet Aggregation (Plug Formation)—GP5—cervical cancer	0.0605	0.0908	CbGpPWpGaD
Apraclonidine—ADRA2C—Platelet Aggregation (Plug Formation)—GP5—cervical cancer	0.0565	0.0848	CbGpPWpGaD
Apraclonidine—ADRA2A—Platelet Aggregation (Plug Formation)—GP5—cervical cancer	0.0459	0.0689	CbGpPWpGaD
Apraclonidine—ADRA2B—Amine ligand-binding receptors—TAAR6—cervical cancer	0.0422	0.0634	CbGpPWpGaD
Apraclonidine—ADRA2C—Amine ligand-binding receptors—TAAR6—cervical cancer	0.0395	0.0592	CbGpPWpGaD
Apraclonidine—ADRA1A—Amine ligand-binding receptors—TAAR6—cervical cancer	0.0345	0.0518	CbGpPWpGaD
Apraclonidine—ADRA2A—Amine ligand-binding receptors—TAAR6—cervical cancer	0.0321	0.0481	CbGpPWpGaD
Apraclonidine—ADRA1A—epithelium—cervical cancer	0.0235	0.0705	CbGeAlD
Apraclonidine—ADRA2C—uterine cervix—cervical cancer	0.0222	0.0666	CbGeAlD
Apraclonidine—ADRA1A—renal system—cervical cancer	0.0218	0.0654	CbGeAlD
Apraclonidine—ADRA2C—decidua—cervical cancer	0.0212	0.0635	CbGeAlD
Apraclonidine—ADRA2C—renal system—cervical cancer	0.0208	0.0623	CbGeAlD
Apraclonidine—ADRA2C—endometrium—cervical cancer	0.0201	0.0602	CbGeAlD
Apraclonidine—ADRA2C—mammalian vulva—cervical cancer	0.0194	0.0583	CbGeAlD
Apraclonidine—ADRA2C—uterus—cervical cancer	0.0185	0.0555	CbGeAlD
Apraclonidine—ADRA2A—uterine cervix—cervical cancer	0.0177	0.0531	CbGeAlD
Apraclonidine—ADRA2A—decidua—cervical cancer	0.0169	0.0506	CbGeAlD
Apraclonidine—ADRA2B—Platelet activation, signaling and aggregation—GP6—cervical cancer	0.0166	0.0249	CbGpPWpGaD
Apraclonidine—ADRA2A—endometrium—cervical cancer	0.016	0.0481	CbGeAlD
Apraclonidine—ADRA2A—mammalian vulva—cervical cancer	0.0155	0.0465	CbGeAlD
Apraclonidine—ADRA2C—Platelet activation, signaling and aggregation—GP6—cervical cancer	0.0155	0.0232	CbGpPWpGaD
Apraclonidine—ADRA2C—female gonad—cervical cancer	0.0151	0.0454	CbGeAlD
Apraclonidine—ADRA2C—vagina—cervical cancer	0.0151	0.0451	CbGeAlD
Apraclonidine—ADRA2A—uterus—cervical cancer	0.0148	0.0443	CbGeAlD
Apraclonidine—ADRA1A—G alpha (12/13) signalling events—AKAP13—cervical cancer	0.0146	0.0219	CbGpPWpGaD
Apraclonidine—ADRA2B—Platelet activation, signaling and aggregation—GP5—cervical cancer	0.0145	0.0217	CbGpPWpGaD
Apraclonidine—ADRA2C—Platelet activation, signaling and aggregation—GP5—cervical cancer	0.0135	0.0203	CbGpPWpGaD
Apraclonidine—ADRA2A—female reproductive system—cervical cancer	0.0133	0.0398	CbGeAlD
Apraclonidine—ADRA2A—Platelet activation, signaling and aggregation—GP6—cervical cancer	0.0126	0.0189	CbGpPWpGaD
Apraclonidine—ADRA2A—female gonad—cervical cancer	0.0121	0.0362	CbGeAlD
Apraclonidine—ADRA2A—vagina—cervical cancer	0.012	0.036	CbGeAlD
Apraclonidine—ADRA2A—Platelet activation, signaling and aggregation—GP5—cervical cancer	0.011	0.0165	CbGpPWpGaD
Apraclonidine—ADRA2C—lymph node—cervical cancer	0.00974	0.0292	CbGeAlD
Apraclonidine—ADRA2B—Hemostasis—GP6—cervical cancer	0.00854	0.0128	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—SERPIND1—cervical cancer	0.00854	0.0128	CbGpPWpGaD
Apraclonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.00831	0.0125	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—SERPIND1—cervical cancer	0.00798	0.012	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—GP6—cervical cancer	0.00798	0.012	CbGpPWpGaD
Apraclonidine—ADRA2A—lymph node—cervical cancer	0.00777	0.0233	CbGeAlD
Apraclonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.00776	0.0116	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—GP5—cervical cancer	0.00747	0.0112	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—GP5—cervical cancer	0.00697	0.0105	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.00678	0.0102	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—SERPIND1—cervical cancer	0.00648	0.00972	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—GP6—cervical cancer	0.00648	0.00972	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—TAAR6—cervical cancer	0.00633	0.00949	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.0063	0.00946	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—TAAR6—cervical cancer	0.00591	0.00887	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—GP5—cervical cancer	0.00566	0.0085	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—TAAR6—cervical cancer	0.00517	0.00775	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—WNT2—cervical cancer	0.00494	0.00741	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—TAAR6—cervical cancer	0.0048	0.0072	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—WNT2—cervical cancer	0.00461	0.00692	CbGpPWpGaD
Apraclonidine—ADRA1A—AMPK Signaling—MTOR—cervical cancer	0.00438	0.00657	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—WNT2—cervical cancer	0.00403	0.00605	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—WNT2—cervical cancer	0.00375	0.00562	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—WNT5A—cervical cancer	0.00374	0.00562	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—TAAR6—cervical cancer	0.00358	0.00537	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—WNT5A—cervical cancer	0.0035	0.00525	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—TAAR6—cervical cancer	0.00334	0.00501	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—TAAR6—cervical cancer	0.00325	0.00487	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—WNT5A—cervical cancer	0.00306	0.00459	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—TAAR6—cervical cancer	0.00303	0.00455	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—TAAR6—cervical cancer	0.00292	0.00438	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—WNT5A—cervical cancer	0.00284	0.00426	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—TAAR6—cervical cancer	0.00271	0.00407	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—TAAR6—cervical cancer	0.00265	0.00398	CbGpPWpGaD
Apraclonidine—ADRA1A—AMPK Signaling—TP53—cervical cancer	0.00258	0.00388	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—WNT2—cervical cancer	0.00253	0.0038	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—TAAR6—cervical cancer	0.00246	0.0037	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—AKAP13—cervical cancer	0.00245	0.00368	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—WNT2—cervical cancer	0.00237	0.00355	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—AKAP13—cervical cancer	0.00229	0.00343	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—AKAP13—cervical cancer	0.00223	0.00334	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—AKAP13—cervical cancer	0.00208	0.00312	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—WNT2—cervical cancer	0.00207	0.00311	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—AKAP13—cervical cancer	0.002	0.003	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—WNT2—cervical cancer	0.00192	0.00289	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—WNT5A—cervical cancer	0.00192	0.00288	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TAAR6—cervical cancer	0.00192	0.00288	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—AKAP13—cervical cancer	0.00186	0.00279	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—AKAP13—cervical cancer	0.00182	0.00273	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—WNT5A—cervical cancer	0.00179	0.00269	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TAAR6—cervical cancer	0.00179	0.00269	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—AKAP13—cervical cancer	0.00169	0.00253	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—CA9—cervical cancer	0.00158	0.00237	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—WNT5A—cervical cancer	0.00157	0.00235	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TAAR6—cervical cancer	0.00157	0.00235	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—WNT2—cervical cancer	0.0015	0.00225	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—WNT5A—cervical cancer	0.00146	0.00219	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TAAR6—cervical cancer	0.00146	0.00218	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—WNT2—cervical cancer	0.0014	0.0021	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—AKAP13—cervical cancer	0.00131	0.00197	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CA9—cervical cancer	0.00128	0.00193	CbGpPWpGaD
Apraclonidine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—cervical cancer	0.00124	0.00186	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—AKAP13—cervical cancer	0.00123	0.00184	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—WNT2—cervical cancer	0.00122	0.00183	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—WNT2—cervical cancer	0.00114	0.0017	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—WNT5A—cervical cancer	0.00113	0.0017	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—AKAP13—cervical cancer	0.00107	0.00161	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—WNT5A—cervical cancer	0.00106	0.00159	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AKAP13—cervical cancer	0.000997	0.0015	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—WNT5A—cervical cancer	0.000927	0.00139	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—WNT5A—cervical cancer	0.000861	0.00129	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—NOTCH2—cervical cancer	0.000797	0.0012	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NOTCH2—cervical cancer	0.000744	0.00112	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—HES1—cervical cancer	0.000653	0.00098	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NOTCH2—cervical cancer	0.00065	0.000976	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—TP53—cervical cancer	0.000643	0.000964	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—MTHFR—cervical cancer	0.000641	0.000962	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—HES1—cervical cancer	0.00061	0.000915	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NOTCH2—cervical cancer	0.000604	0.000907	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—TP53—cervical cancer	0.0006	0.000901	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TERT—cervical cancer	0.000572	0.000859	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TERT—cervical cancer	0.000535	0.000802	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—HES1—cervical cancer	0.000533	0.0008	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—FGFR3—cervical cancer	0.000525	0.000788	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—MTHFR—cervical cancer	0.000521	0.000781	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—HES1—cervical cancer	0.000495	0.000743	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—NOTCH1—cervical cancer	0.000493	0.00074	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—FGFR3—cervical cancer	0.000491	0.000736	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—TP53—cervical cancer	0.000488	0.000732	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TERT—cervical cancer	0.000467	0.000701	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NOTCH1—cervical cancer	0.000461	0.000691	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—EGFR—cervical cancer	0.000439	0.000659	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TERT—cervical cancer	0.000434	0.000651	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—FGFR3—cervical cancer	0.000429	0.000643	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—EGFR—cervical cancer	0.00041	0.000616	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NOTCH1—cervical cancer	0.000403	0.000604	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—FGFR3—cervical cancer	0.000398	0.000598	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NOTCH1—cervical cancer	0.000374	0.000561	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MTOR—cervical cancer	0.000369	0.000554	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—EGFR—cervical cancer	0.000359	0.000538	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MTOR—cervical cancer	0.000345	0.000518	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CASP3—cervical cancer	0.00034	0.00051	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—EGFR—cervical cancer	0.000333	0.0005	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CTNNB1—cervical cancer	0.000328	0.000491	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CASP3—cervical cancer	0.000317	0.000476	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CTNNB1—cervical cancer	0.000306	0.000459	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MTOR—cervical cancer	0.000302	0.000453	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—STAT3—cervical cancer	0.000286	0.000428	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MTOR—cervical cancer	0.00028	0.000421	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CASP3—cervical cancer	0.000277	0.000416	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CTNNB1—cervical cancer	0.000267	0.000401	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—STAT3—cervical cancer	0.000267	0.0004	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—EGFR—cervical cancer	0.000259	0.000389	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CASP3—cervical cancer	0.000258	0.000387	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CTNNB1—cervical cancer	0.000249	0.000373	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—EGFR—cervical cancer	0.000242	0.000364	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—STAT3—cervical cancer	0.000233	0.00035	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TP53—cervical cancer	0.000218	0.000327	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—STAT3—cervical cancer	0.000217	0.000325	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—EGFR—cervical cancer	0.000212	0.000318	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TP53—cervical cancer	0.000204	0.000305	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—EGFR—cervical cancer	0.000197	0.000295	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TP53—cervical cancer	0.000178	0.000267	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TP53—cervical cancer	0.000165	0.000248	CbGpPWpGaD
